Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial
This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma.
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 21, 2020
|
| In: |
JAMA oncology
Year: 2020, Jahrgang: 6, Heft: 7, Pages: 1003-1010 |
| ISSN: | 2374-2445 |
| DOI: | 10.1001/jamaoncol.2020.1024 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamaoncol.2020.1024 Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/ 
|
| Verfasserangaben: | David A. Reardon, MD; Alba A. Brandes, MD; Antonio Omuro, MD; Paul Mulholland, PhD; Michael Lim, MD; Antje Wick, MD; Joachim Baehring, MD; Manmeet S. Ahluwalia, MD; Patrick Roth, MD; Oliver Bähr, MD; Surasak Phuphanich, MD; Juan Manuel Sepulveda, MD, PhD; Paul De Souza, MD; Solmaz Sahebjam, MD; Michael Carleton, PhD; Kay Tatsuoka, PhD; Corina Taitt, MD; Ricardo Zwirtes, MD; John Sampson, MD; Michael Weller, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1738081265 | ||
| 003 | DE-627 | ||
| 005 | 20220819014445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201106s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamaoncol.2020.1024 |2 doi | |
| 035 | |a (DE-627)1738081265 | ||
| 035 | |a (DE-599)KXP1738081265 | ||
| 035 | |a (OCoLC)1341375910 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Reardon, David A. |e VerfasserIn |0 (DE-588)1081843225 |0 (DE-627)846734494 |0 (DE-576)454837860 |4 aut | |
| 245 | 1 | 0 | |a Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma |b the checkmate 143 phase 3 randomized clinical trial |c David A. Reardon, MD; Alba A. Brandes, MD; Antonio Omuro, MD; Paul Mulholland, PhD; Michael Lim, MD; Antje Wick, MD; Joachim Baehring, MD; Manmeet S. Ahluwalia, MD; Patrick Roth, MD; Oliver Bähr, MD; Surasak Phuphanich, MD; Juan Manuel Sepulveda, MD, PhD; Paul De Souza, MD; Solmaz Sahebjam, MD; Michael Carleton, PhD; Kay Tatsuoka, PhD; Corina Taitt, MD; Ricardo Zwirtes, MD; John Sampson, MD; Michael Weller, MD |
| 264 | 1 | |c May 21, 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.11.2020 | ||
| 520 | |a This randomized clinical trial examines the effect of programmed cell death 1 immune checkpoint inhibition with nivolumab on overall survival for patients with recurrent glioblastoma. | ||
| 700 | 1 | |a Brandes, Alba A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Omuro, Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mulholland, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lim, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a Baehring, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ahluwalia, Manmeet S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Roth, Patrick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bähr, Oliver |e VerfasserIn |4 aut | |
| 700 | 1 | |a Phuphanich, Surasak |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sepulveda, Juan Manuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a De Souza, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sahebjam, Solmaz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Carleton, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tatsuoka, Kay |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taitt, Corina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zwirtes, Ricardo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sampson, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weller, Michael |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA oncology |d Chicago, Ill. : American Medical Association, 2015 |g 6(2020), 7, Seite 1003-1010 |h Online-Ressource |w (DE-627)818494301 |w (DE-600)2810928-4 |w (DE-576)426501284 |x 2374-2445 |7 nnas |a Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma the checkmate 143 phase 3 randomized clinical trial |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:7 |g pages:1003-1010 |g extent:8 |a Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma the checkmate 143 phase 3 randomized clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1001/jamaoncol.2020.1024 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243167/ |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201106 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 910000 |e 910000PW122759869 |k 0/910000/ |p 6 | ||
| 999 | |a KXP-PPN1738081265 |e 3793353591 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma","subtitle":"the checkmate 143 phase 3 randomized clinical trial","title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma"}],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["David A. Reardon, MD; Alba A. Brandes, MD; Antonio Omuro, MD; Paul Mulholland, PhD; Michael Lim, MD; Antje Wick, MD; Joachim Baehring, MD; Manmeet S. Ahluwalia, MD; Patrick Roth, MD; Oliver Bähr, MD; Surasak Phuphanich, MD; Juan Manuel Sepulveda, MD, PhD; Paul De Souza, MD; Solmaz Sahebjam, MD; Michael Carleton, PhD; Kay Tatsuoka, PhD; Corina Taitt, MD; Ricardo Zwirtes, MD; John Sampson, MD; Michael Weller, MD"]},"note":["Gesehen am 06.11.2020"],"id":{"eki":["1738081265"],"doi":["10.1001/jamaoncol.2020.1024"]},"recId":"1738081265","origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"May 21, 2020"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"David A.","role":"aut","display":"Reardon, David A.","family":"Reardon"},{"given":"Alba A.","family":"Brandes","display":"Brandes, Alba A.","role":"aut"},{"display":"Omuro, Antonio","family":"Omuro","role":"aut","given":"Antonio"},{"given":"Paul","role":"aut","family":"Mulholland","display":"Mulholland, Paul"},{"given":"Michael","role":"aut","display":"Lim, Michael","family":"Lim"},{"family":"Wick","display":"Wick, Antje","role":"aut","given":"Antje"},{"role":"aut","display":"Baehring, Joachim","family":"Baehring","given":"Joachim"},{"given":"Manmeet S.","role":"aut","family":"Ahluwalia","display":"Ahluwalia, Manmeet S."},{"given":"Patrick","role":"aut","display":"Roth, Patrick","family":"Roth"},{"given":"Oliver","role":"aut","display":"Bähr, Oliver","family":"Bähr"},{"role":"aut","display":"Phuphanich, Surasak","family":"Phuphanich","given":"Surasak"},{"given":"Juan Manuel","role":"aut","display":"Sepulveda, Juan Manuel","family":"Sepulveda"},{"given":"Paul","display":"De Souza, Paul","family":"De Souza","role":"aut"},{"display":"Sahebjam, Solmaz","family":"Sahebjam","role":"aut","given":"Solmaz"},{"given":"Michael","display":"Carleton, Michael","family":"Carleton","role":"aut"},{"display":"Tatsuoka, Kay","family":"Tatsuoka","role":"aut","given":"Kay"},{"given":"Corina","role":"aut","family":"Taitt","display":"Taitt, Corina"},{"given":"Ricardo","role":"aut","display":"Zwirtes, Ricardo","family":"Zwirtes"},{"role":"aut","display":"Sampson, John","family":"Sampson","given":"John"},{"display":"Weller, Michael","family":"Weller","role":"aut","given":"Michael"}],"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"818494301","part":{"text":"6(2020), 7, Seite 1003-1010","issue":"7","extent":"8","year":"2020","pages":"1003-1010","volume":"6"},"disp":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma the checkmate 143 phase 3 randomized clinical trialJAMA oncology","pubHistory":["1.2015 -"],"corporate":[{"display":"American Medical Association","role":"isb"}],"origin":[{"publisher":"American Medical Association","dateIssuedKey":"2015","publisherPlace":"Chicago, Ill.","dateIssuedDisp":"2015-"}],"id":{"zdb":["2810928-4"],"eki":["818494301"],"issn":["2374-2445"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"JAMA oncology","title_sort":"JAMA oncology"}],"note":["Gesehen am 12.10.2017"]}]} | ||
| SRT | |a REARDONDAVEFFECTOFNI2120 | ||